The INK4A/ARF network - Cell cycle checkpoint or emergency brake?

Advances in Experimental Medicine and Biology

Volumn 570, Issue , 2005, Pages 227-247

  Del Arroyo, Ana Gutierrez ^a   Peters, Gordon ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; PROTEIN P14ARF; PROTEIN P16INK4A;

CANCER SUSCEPTIBILITY; CELL CYCLE ARREST; CHROMOSOME; FRAMESHIFT MUTATION; GENE LOCUS; GENOMIC INSTABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SENESCENCE;

ADP-RIBOSYLATION FACTORS; AGING; AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENOMIC INSTABILITY; HUMANS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; SIGNAL TRANSDUCTION;

EID: 34548682773     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (155)

1. Agami, R., and R. Bernards. 2000. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell. 102:55-66.
2. Alcorta, D.A., Y. Xiong, D. Phelps, G. Hannon, D. Beach, and J.C. Barrett. 1996. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence. Proc. Natl. Acad. Sci. USA. 93:13742-13747.
3. Aslanian, A., P.J. Iaquinta, R. Verona, and J.A. Lees. 2004. Repression of the Arf tumor suppressor by E2F3 is required for normal cel cycle kinetics. Genes & Dev. 18:1413-1422.
4. ARF links the tumour suppressors RB and p53. Nature. 395:124-125.
5. Benanti, J.A., and D.A. Galloway. 2004. Normal human fibroblasts are resistant to RAS-induced senescence. Mol. Cell. Biol. 24:2842-2852.
6. Bertwistle, D., M. Sugimoto, and C.J. Sherr. 2004. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol. Cell. Biol. 24:985-996.
7. Blattner, C., A. Sparks, and D. Lane. 1999. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol. Cell. Biol. 19:3704-3713.
8. Bodnar, A.G., M. Ouellette, M. Frolkis, S.E. Holt, C.-P. Chiu, G.B. Morin, C.B. Harley, J.W. Shay, S. Lichsteiner, and W.E. Wright. 1998. Extension of life-span by introduction of telomerase into normal human cells. Science. 279:349-352.
9. Bothner, B., W.S. Lewis, E.L. DiGiammarino, J.D. Weber, S.J. Bothner, and R.W. Kriwacki. 2001. Defining the molecular basis of Arf and Hdm2 interactions. J. Mol. Biol. 314:263-277.
10. Brenner, A.J., M.R. Stampfer, and C.M. Aldaz. 1998. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene. 17:199-205.
11. INK4a to replicative senescence of human fibroblasts. Exp. Cell Res. 298:549-559.
12. Brookes, S., J. Rowe, M. Ruas, S. Llanos, P.A. Clark, M. Lomax, M.C. James, R. Vatcheva, S. Bates, K.H. Vousden, D. Parry, N. Gruis, N. Smit, W. Bergman, and G. Peters. 2002. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J. 21:2936-2945.
13. Bulavin, D.V., O.N. Demidov, S. Saito, P. Kauraniemi, C. Phillips, S.A. Amundson, C. Ambrosino, G. Sauter, A.R. Nebreda, C.W. Anderson, A. Kallioniemi, A.J. Fornace Jr., and E. Appella. 2002. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat. Genet. 31:210-215.
14. Bulavin, D.V., S. Saito, M.C. Hollander, K. Sakaguchi, C.W. Anderson, E. Appella, and A.J. Fornace Jr. 1999. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 18:6845-6854.
15. ARF, and p300/CBP during the cell cycle and after exposure to ultraviolet irradiation. Cancer Res. 60:896-900.
16. Campisi, J. 1997. The biology of replicative senescence. Eur. J. Cancer. 33:703-709.
17. Chen, Q., A. Fischer, J.D. Reagan, L.J. Yan, and B.N. Ames. 1995. Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc. Natl. Acad. Sci. USA. 92:4337-4341.
18. ARF mediated inhibition of MDM2. Oncogene. 21:4498-4507.
19. d'Adda di Fagagna, F., P.M. Reaper, L. Clay-Farrace, H. Fiegler, P. Carr, T. von Zglinicki, G. Saretzki, N.P. Carter, and S.P. Jackson. 2003. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 426:194-198.
20. Datta, A., A. Nag, W. Pan, N. Hay, A.L. Gartel, O. Colamonici, Y. Mori, and P. Raychaudhuri. 2004. Myc-ARF (alternative reading frame) interaction inhibits the functions of Myc. J. Biol. Chem. 279:36698-36707.
21. Datta, B., A. Nag, and P. Raychaudhuri. 2002. Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF. Mol. Cell. Biol. 22:8398-8408.
22. ARF tumor suppressor. Genes Dev. 12:2434-2442.
23. DeGregori, J., G. Leone, A. Miron, L. Jakoi, and J.R. Nevins. 1997. Distinct roles for E2F proteins in cell growth control. Proc. Natl. Acad. Sci. USA. 94:7245-7250.
24. Deng, Q., R. Liao, B.-L. Wu, and P. Sun. 2004. High intensity ras signaling induces premature senescence by activating p38 pathway in primary human fibroblasts. J. Biol. Chem. 279:1050-1059.
25. INK4a-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol. Cell. Biol. 20:1436-1447.
26. ARF tumor suppressor. Mol. Cell. Biol. 20:273-285.
27. Drayton, S., and G. Peters. 2002. Immortalisation and transformation revisited. Curr. Opin. Genet. Dev. 12:98-104.
28. INK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes. Cancer Cell. 4:301-310.
29. INK4a methylation and p53 mutational status. Cancer Res. 60:129-133.
30. Eymin, B., L. Karayan, P. Séité, C. Brambilla, E. Brambilla, C.-J. Larsen, and S. Gazzéri. 2001. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene. 20:1033-1041.
31. Falck, J., N. Mailand, R.G. Syljuåsen, J. Bartek, and J. Lukas. 2001. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature. 410:842-847.
32. ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1α (HIF-1α) and inhibits HIF-1-mediated transcription. J. Biol. Chem. 276:28421-28429.
33. Felsher, D.W., and J.M. Bishop. 1999. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. USA. 96:3940-3944.
34. Ferbeyre, G., E. de Stanchina, E. Querido, N. Baptiste, C. Prives, and S.W. Lowe. 2000. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14:2015-2027.
35. Foster, S.A., D.J. Wong, M.T. Barrett, and D.A. Galloway. 1998. Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol. Cell. Biol. 18:1793-1801.
36. Gil, J., D. Bernard, D. Martinez, and D. Beach. 2004. Polycomb CBX7 has a unifying role in cellular lifespan. Nature Cell Biol. 6:67-72.
37. Gilley, J., and M. Fried. 2001. One INK4 gene and no ARF at the Fugu equivalent of the human INK4A/ARF/INK4B tumour suppressor locus. Oncogene. 20:7447-7452.
38. Gorbunova, V., A. Seluanov, and O.M. Pereira-Smith. 2002. Expression of human telomerase (hTERT) does not prevent stress-induced senescence in normal human fibroblasts but protects the cells from stress-induced apoptosis and necrosis. J. Biol. Chem. 277:38540-38549.
39. Haq, R., J.D. Brenton, M. Takahashi, D. Finan, R. Rottapel, and B. Zanke. 2002. Constitutive p38HOG mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. Cancer Res. 62:5067-5082.
40. Hara, E., R. Smith, D. Parry, H. Tahara, S. Stone, and G. Peters. 1996. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 16:859-867.
41. Harley, C.B. 1991. Telomere loss: mitotic clock or genetic time bomb? Mutat. Res. 256:271-282.
42. Hayflick, L. 1965. The limited in vitro lifespan of human diploid cell strains. Exp. Cell Res. 37:614-636.
43. INK4a. Mol. Cell. 14:501-513.
44. Hewitt, C., C.L. Wu, G. Evans, A. Howell, R.G. Elles, R. Jordan, P. Sloan, A.P. Read, and N. Thakker. 2002. Germline mutation of ARF in a melanoma kindred. Hum. Mol. Genet. 11:1273-1279.
45. Hirai, H., M.F. Roussel, J.-Y. Kato, R.A. Ashmun, and C.J. Sherr. 1995. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol. 15:2672-2681.
46. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumour suppressor p53. EMBO J. 18:22-27.
47. INK4a confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts. Mol. Cell. Biol. 22:8135-8143.
48. INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res. 58:3508-3512.
49. Itahana, K., K.P. Bhat, A. Jin, Y. Itahana, D. Hawke, R. Kobayashi, and Y. Zhang. 2003a. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell. 12:1151-1164.
50. Itahana, K., Y. Zou, Y. Itahana, J.-L. Martinez, C. Beausejour, J.J.L. Jacobs, M. van Lohuizen, V. Band, J. Campisi, and G.P. Dimri. 2003b. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol. Cell. Biol. 23:389-401.
51. Iwasa, H., J. Han, and F. Ishikawa. 2003. Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway. Genes to Cells. 8:131-144.
52. Jacobs, J.J.L., P. Keblusek, E. Robanus-Maandag, P. Kristel, M. Lingbeek, P.M. Nederlof, T. van Welsem, M.J. van de Vijver, E.Y. Koh, G.Q. Daley, and M. van Lohuizen. 2000. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19ARF) and is amplified in a subset of human breast cancers. Nature Genet. 291:291-299.
53. Jacobs, J.J.L., K. Kieboom, S. Marino, R.A. DePinho, and M. van Lohuizen. 1999. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 397:164-168.
54. INK4a-mediated growth suppression. Mol. Cell. Biol. 18:5284-5290.
55. Kamijo, T., S. Bodner, E. van de Kamp, D.H. Randle, and C.J. Sherr. 1999a. Tumor spectrum in ARF-deficient mice. Cancer Res. 59:2217-2222.
56. Kamijo, T., E. van de Kamp, M.J. Chong, F. Zindy, J.A. Diehl, C.J. Sherr, and P.J. McKinnon. 1999b. Loss of ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled Atm function. Cancer Res. 59:2464-2469.
57. Kamijo, T., J.D. Weber, G. Zambetti, F. Zindy, M.F. Roussel, and C.J. Sherr. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA. 95:8292-8297.
58. ARF. Cell. 91:649-659.
59. Karayan, L., J.-F. Riou, P. Séité, J. Migeon, A. Cantereau, and C.-J. Larsen. 2001. Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene. 20:836-848.
60. Kashuba, E., K. Mattson, G. Klein, and L. Szekely. 2004. p14ARF induces the relocation of HDM2 and p53 to extranucleolar sites that are targeted by PML bodies and proteasomes. Mol. Cancer. 2:18.
61. Kazianis, S., D.C. Morizot, L. Della Coletta, D.A. Johnston, B. Woolcock, J.R. Vielkind, and R.S. Nairn. 1999. Comparative structure and characterization of a CDKN2 gene in a Xiphophorus fish melanoma model. Oncogene. 18:5088-5099.
62. Khan, S., C. Guevara, G. Fujii, and D. Parry. 2004. p14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts. Oncogene. 23:6040-6046.
63. ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucloetide depletion. Proc. Natl. Acad. Sci. USA. 97:3266-3271.
64. INK4a and truncation of ARF tumor suppressors in chickens. Proc. Natl. Acad. Sci. USA. 100:211-216.
65. INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature. 396:84-88.
66. Korgaonkar, C., L. Zhao, M. Modestou, and D.E. Quelle. 2002. ARF function does not require p53 stabilization or Mdm2 relocalization. Mol. Cell. Biol. 22:196-206.
67. Kozar, K., M.A. Ciemerych, V.I. Rebel, H. Shigematsu, A. Zagozdzon, E. Sicinska, Y. Geng, Q. Yu, S. Batthacharya, R.T. Bronson, K. Akashi, and P. Sicinski. 2004. Mouse development and cell proliferation in the absence of D-cyclins. Cell. 118:477-491.
68. Ink4a confers susceptibility to metastatic melanoma in mice. Nature. 413:83-86.
69. Kuo, M.-L., W. den Besten, D. Bertwistle, M.F. Roussel, and C.J. Sherr. 2004. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes & Dev. 18:1862-1874.
70. Li, Y., M.A. Nichols, J.W. Shay, and Y. Xiong. 1994. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 54:6078-6082.
71. ARF. Oncogene. 23:7355-7365.
72. Lin, A.W., and S.W. Lowe. 2001. Oncogenic ras activates the ARF-p53 pathway to suppress epthelial cell transformation. Proc. Natl. Acad. Sci. USA. 98:5025-5030.
73. Lin, W.-C., F.-T. Lin, and J.R. Nevins. 2001. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 15:1833-1844.
74. ARF to the granular component of the interphase nucleus. Exp. Cell Res. 256:400-410.
75. ARF without relocation of MDM2 to the nucleolus. Nature Cell Biol. 3:445-452.
76. ARF to p53 stabilization. Curr. Biol. 10:539-542.
77. Lohrum, M.A.E., M. Ashcroft, M.H.G. Kubbutat, and K.H. Vousden. 2000b. Identification of a cryptic nucleolar-localization signal in MDM2. Nature Cell Biol. 2:179-181.
78. Lomazzi, M., M.C. Moroni, M.R. Jensen, E. Frittoli, and K. Helin. 2002. Suppression of the p53- or pRB-mediated G1 checkpoint is required for E2F-induced S-phase entry. Nat. Genet. 31:190-194.
79. Lund, A.H., and M. van Lohuizen. 2004. Polycomb complexes and silencing mechanisms. Curr. Opin. Cell Biol. 16:239-246.
80. Malumbres, M., R. Sotillo, D. Santamaria, J. Galan, A. Cerezo, S. Ortega, P. Dubus, and M. Barbacid. 2004. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 118:493-504.
81. ARF targets certain E2F species for degradation. Proc. Natl. Acad. Sci. USA. 8:4455-4460.
82. Masutomi, K., E.Y. Yu, S. Khurts, I. Ben-Porath, J.L. Currier, G.B. Metz, M.W. Brooks, S. Kaneko, S. Murakami, J.A. DeCaprio, R.A. Weinberg, S.A. Stewart, and W.C. Hahn. 2003. Telomerase maintains telomere structure in normal human cells. Cell. 114:241-253.
83. Maya, R., M. Balass, S.-T. Kim, D. Shkedy, J.-F.M. Leal, O. Shifman, M. Moas, T. Buschmann, Z. Ronai, Y. Shiloh, M.B. Kastan, E. Katzir, and M. Oren. 2001. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes & Dev. 15:1067-1077.
84. INK4a inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol. Cell. Biol. 19:1981-1989.
85. waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene. 16:431-441.
86. Michael, D., and M. Oren. 2003. The p53-Mdm2 module and the ubiquitin system. Sem. Cancer Biol. 13:49-58.
87. ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene. 19:2312-2323.
88. Modestou, M., V. Puig-Antich, C. Korgaonkar, A. Eapen, and D.E. Quelle. 2001. The alternative reading frame tumor suppressor inhibits growth through p21-dependent and p21-independent pathways. Cancer Res. 61:3145-3150.
89. Morales, C.P., S.E. Holt, M. Ouellette, K.J. Kaur, Y. Yan, K.S. Wilson, M.A. White, W.E. Wright, and J.W. Shay. 1999. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat. Genet. 21:115-118.
90. Morris, M., P. Hepburn, and D. Wynford-Thomas. 2002. Sequential extension of proliferative lifespan in human fibroblasts induced by over-expression of CDK4 or 6 and loss of p53 function. Oncogene. 21:4277-4288.
91. Munro, J., N.I. Barr, H. Ireland, V. Morrison, and E.K. Parkinson. 2004. Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. Exp. Cell Res. 295:528-538.
92. INK4A upon immortalization. Cancer Res. 59:2516-2521.
93. Naka, K., A. Tachibana, K. Ikeda, and N. Motoyama. 2004. Stress-induced premature senescence in hTERT-expressing Ataxia-telangiectasia fibroblasts. J. Biol. Chem. 279:2030-2037.
94. Newbold, R.F., and R.W. Overell. 1983. Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature. 304:648-651.
95. 2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell. Biol. 18:629-643.
96. Ogryzko, V.V., T.H. Hirai, V.R. Russanova, D.A. Barbie, and B.H. Howard. 1996. Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol. Cell. Biol. 16:5210-5218.
97. Ortega, S., I. Prieto, J. Odajima, A. Martin, P. Dubus, R. Sotillo, J.L. Barbero, M. Malumbres, and M. Barbacid. 2003. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 35:25-31.
98. ARF by E2F1, E2F2, E2F3, and Sp1-like factors. Biochem. Biophys. Res. Commun. 291:1138-1145.
99. Parrinello, S., E. Samper, A. Krtolica, J. Goldstein, S. Melov, and J. Campisi. 2003. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat. Cell. Biol. 5:741-747.
100. INK4/MTS1 tumour suppressor gene product. EMBO J. 14:503-511.
101. Pollice, A., V. Nasti, R. Ronca, M. Vivo, M. Lo Iacono, R. Calogero, V. Calabrò, and G. La Mantia. Functional and physical interaction of the human ARF tumor suppressor with Tat-binding protein-1. J. Biol. Chem. 279:6345-6353.
102. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:713-723.
103. ARF directly and differentially controls the functions of c-Myc independently of p53. Nature.
104. ARF. Proc. Natl. Acad. Sci. USA. 94:669-673.
105. Quelle, D.E., F. Zindy, R.A. Ashmun, and C.J. Sherr. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83:993-1000.
106. Ramirez, R.D., C.P. Morales, B.-S. Herbert, J.M. Rohde, C. Passons, J.W. Shay, and W.E. Wright. 2001. Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev. 15:398-403.
107. ARF but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum. Mol. Genet. 10:55-62.
108. Rangarajan, A., and R.A. Weinberg. 2003. Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev. Cancer. 3:952-959.
109. Rizos, H., A.P. Darmanian, G.J. Mann, and R.F. Kefford. 2000. Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. Oncogene. 19:2978-2985.
110. Robertson, K.D., and P.A. Jones. 1998. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down regulated by wild-type p53. Mol. Cell. Biol. 18:6457-6473.
111. INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene. 16:1113-1123.
112. ARF. Oncogene. 23:6186-6192.
113. INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta. 1378:115-177.
114. Rubbi, C.P., and J. Milner. 2003. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 22:6068-6077.
115. Russell, J.L., J.T. Powers, R.J. Rounbehler, P.M. Rogers, C.J. Conti, and D.G. Johnson. 2002. ARF differentially modulates apoptosis induced by E2F1 and Myc. Mol. Cell. Biol. 22:1360-1368.
116. Serrano, M., G.J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:704-707.
117. INK4a. Cell. 88:593-602.
118. Arf predisposes mice to tumorigenesis. Nature. 413:86-91.
119. Sharpless, N.E., and R.A. DePinho. 1999. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9:22-30.
120. Sherr, C.J. 2001. The INK4a/ARF network in tumour suppression. Nature Reviews. 2:731-737.
121. Sherr, C.J., and R.A. DePinho. 2000. Cellular senescence: mitotic clock or culture shock? Cell. 102:407-410.
122. Sherr, C.J., and F. McCormick. 2002. The RB and p53 pathways in cancer. Cancer Cell. 2:103-112.
123. Smogorzewska, A., and T. de Lange. 2002. Different telomere damage signaling pathways in human and mouse cells. EMBO J. 21:4338-4348.
124. Soucek, T., O. Pusch, E. Hengstschläger-Ottnad, E. Wawra, G. Bernaschek, and M. Hengstschläger. 1995. Expression of the cyclin-dependent kinase inhibitor p16 during the ongoing cell cycle. FEBS Lett. 373:164-169.
125. Stein, G.H., L.F. Drullinger, A. Soulard, and V. Dulic. 1999. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol. Cell. Biol. 19:2109-2117.
126. Stone, S., P. Jiang, P. Dayanath, S.V. Tavtigian, H. Katcher, D. Parry, G. Peters, and A. Kamb. 1995. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res. 55:2988-2994.
127. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:5001-5014.
128. Sugihara, T., S.C. Kaul, J. Kato, R.R. Reddel, H. Nomura, and R. Wadhwa. 2001. Pex19p dampens the p19ARF-p53-p21WAF1 tumor suppressor pathway. J. Biol. Chem. 276:18649-18652.
129. Sugimoto, M., M.-L. Kuo, M.F. Roussel, and C.J. Sherr. 2003. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol. Cell. 11:415-424.
130. Takekawa, M., M. Adachi, A. Nakahata, I. Nakayama, F. Itoh, H. Tsukuda, Y. Taya, and K. Imai. 2000. p53-inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J. 19:6517-6526.
131. Ink4. Cancer Res. 54:5816-5820.
132. ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. USA. 96:6937-6941.
133. Vafa, O., M. Wade, S. Kern, M. Beeche, T.K. Pandita, G.M. Hampton, and G.M. Wahl. 2002. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell. 9:1031-1044.
134. van Lohuizen, M., S. Verbeek, B. Scheijen, E. Wientjens, H. van der Gulden, and B. A. 1991. Identification of cooperating oncogenes in Eμ-myc transgenic mice. Cell. 65:737-752.
135. Vaziri, H., and S. Benchimol. 1998. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative lifespan. Curr. Biol. 8:279-282.
136. Vivo, M., R.A. Calogero, F. Sansone, V. Calabro, T. Parisi, L. Borrelli, S. Saviozzi, and G. La Mantia. 2001. The human tumor suppressor ARF interacts with spinophilin/neurabin II, a type 1 protein-phosphatase-binding protein. J. Biol. Chem. 276:14161-14169.
137. Voorhoeve, M., and R. Agami. 2003. The tumor-suppressive functions of the human INK4A locus. Cancer Cell. 4:311-319.
138. Wang, W., J.X. Chen, R. Liao, Q. Deng, J.J. Zhou, S. Huang, and P. Sun. 2002. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogena-ctivated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol. Cell. Biol. 22:3389-3403.
139. Wang, X.-F., C.H. McGowan, M. Zhao, L. He, J.S. Downey, C. Fearns, Y. Wang, S. Huang, and J. Han. 2000. Involvement of the MKK6-p38γ cascade in γ-radiation-induced cell cycle arrest. Mol. Cell. Biol. 20:4543-4552.
140. 2-phase cell cycle delay. Cancer Res. 56:2510-2514.
141. ARF-mediated cell cycle arrest strictly depends on intact p53 signaling pathways. Oncogene. 21:3207-3212.
142. ARF tumor suppressor. Genes Dev. 14:2358-2365.
143. Weber, J.D., M.-L. Kuo, B. Bothner, E.L. DiGiammarino, R.W. Kriwacki, M.F. Roussel, and C.J. Sherr. 2000b. Cooperative signals governing ARF-MDM2 interaction and nucleolar localization of the complex. Mol. Cell. Biol. 20:2517-2528.
144. Weber, J.D., L.J. Taylor, M.F. Roussel, C.J. Sherr, and D. Bar-Sagi. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biol. 1:20-26.
145. Wei, S., W. Wei, and J.M. Sedivy. 1999. Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts. Cancer Res. 59:1539-1543.
146. ARF in replicative and induced senescence of human fibroblasts. Mol. Cell. Biol. 21:6748-6757.
147. Wei, W., U. Herbig, A. Dutriaux, and J.M. Sedivy. 2003. Loss of retinoblastoma but not p16 function allows bypass of replicative senescence in human fibroblasts. Embo Rep. 4:1061-1066.
148. Wright, W., and J.W. Shay. 2000. Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology. Nature Med. 6:849-851.
149. Wright, W.E., and J.W. Shay. 2002. Historical claims and current interpretations of replicative aging. Nat. Biotechnol. 20:682-688.
150. Yarbrough, W.G., M. Bessho, A. Zanation, J.E. Bisi, and Y. Xiong. 2002. Human tumor suppressor ARF impedes S-phase progression independent of p53. Cancer Res. 62:1171-1177.
151. Zhang, Y., and Y. Xiong. 1999. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Molec. Cell. 3:579-591.
152. Zhang, Y., Y. Xiong, and W.G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:725-734.
153. Zindy, F., C.M. Eischen, D.H. Randle, T. Kamijo, J.L. Cleveland, C.J. Sherr, and M.F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:2424-2433.
154. INK4A tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene. 15:203-211.
155. Zindy, F., R.T. Williams, T.A. Baudino, J.E. Rehg, S.X. Skapek, J.L. Cleveland, M.F. Roussel, and C.J. Sherr. 2003. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc. Natl. Acad. Sci. USA. 100:15930-15935.